Leo Pharma’s new psoriasis drug wins European approval
The UK will be the first country to market Xamiol. This will take place in the fourth quarter of 2008. Prior to the approval of Xamiol, Leo Pharma
Vertex has signed a definitive agreement to purchase Crinetics Pharmaceuticals in a transaction valued at nearly $10bn, or $8.8bn net of estimated cash acquired.